Literature DB >> 15289604

Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells.

Changyong Lu1, John Cijiang He, Weijing Cai, Huixian Liu, Li Zhu, Helen Vlassara.   

Abstract

Advanced glycation endproducts (AGE) contribute to kidney disease due to diabetes or aging by means of mesangial cell (MC) receptors, such as the receptor for AGE (RAGE), which promote oxidant-stress-dependent NF-kappaB activation and inflammatory gene expression. MC also express scavenger receptors SR-I and SR-II and AGE receptors 1, 2, and 3 (AGE-R1, -R2, and -R3), some of which are linked to AGE turnover. Because AGE-R1 expression is found suppressed in severe diabetic kidney disease, as other receptors increase, we investigated whether his molecule has a protective role against AGE-induced MC injury. A stable murine MC line overexpressing AGE-R1 (R1-MC) was generated, exhibiting a 1.8- to 2.7-fold increase in (125)I-AGE-specific binding, uptake, and degradation, compared with mock-MC. However, AGE-stimulated NF-kappaB activity and mitogen-activated protein kinase (MAPK) (p44/42) phosphorylation were found markedly suppressed in R1-MC. Additionally, AGE-stimulated macrophage chemotaxis protein 1 and RAGE overexpression were abolished in R1-MC. The effect of R1 on RAGE signaling was investigated after overexpressing RAGE in Chinese hamster ovary cells, which lack RAGE. AGE stimulation elicited NF-kappaB and MAPK activities in RAGE-Chinese hamster ovary cells; however, after cotransfection with R1, these responses were suppressed. Also, after silencing endogenous R1 in wild-type MC by R1 small interfering RNA, AGE-mediated MAPK/p44/42 activation exceeded by >2-fold that of mock-MC, consistent with loss of the activation-inhibitory properties of native AGE-R1. AGE-R1, although enhancing AGE removal, is also a distinct receptor in that it suppresses AGE-mediated MC inflammatory injury through negative regulation of RAGE, a previously uncharacterized pathway that may protect renal and other tissue injury due to diabetes and aging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289604      PMCID: PMC511050          DOI: 10.1073/pnas.0401588101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.

Authors:  M A Hofmann; S Drury; C Fu; W Qu; A Taguchi; Y Lu; C Avila; N Kambham; A Bierhaus; P Nawroth; M F Neurath; T Slattery; D Beach; J McClary; M Nagashima; J Morser; D Stern; A M Schmidt
Journal:  Cell       Date:  1999-06-25       Impact factor: 41.582

2.  Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.

Authors:  T Soulis; V Thallas; S Youssef; R E Gilbert; B G McWilliam; R P Murray-McIntosh; M E Cooper
Journal:  Diabetologia       Date:  1997-06       Impact factor: 10.122

3.  Cell to cell interaction between mesangial cells and macrophages induces the expression of monocyte chemoattractant protein-1 through nuclear factor-kappaB activation.

Authors:  Y Hisada; H Sakurai; T Sugaya
Journal:  Biochem Biophys Res Commun       Date:  2000-03-16       Impact factor: 3.575

4.  Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells.

Authors:  H Tsuji; N Iehara; T Masegi; M Imura; J Ohkawa; H Arai; K Ishii; T Kita; T Doi
Journal:  Biochem Biophys Res Commun       Date:  1998-04-17       Impact factor: 3.575

5.  Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress.

Authors:  H M Lander; J M Tauras; J S Ogiste; O Hori; R A Moss; A M Schmidt
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

6.  N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.

Authors:  T Kislinger; C Fu; B Huber; W Qu; A Taguchi; S Du Yan; M Hofmann; S F Yan; M Pischetsrieder; D Stern; A M Schmidt
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

7.  Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration.

Authors:  C He; J Sabol; T Mitsuhashi; H Vlassara
Journal:  Diabetes       Date:  1999-06       Impact factor: 9.461

8.  Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells.

Authors:  Y Iwashima; M Eto; S Horiuchi; H Sano
Journal:  Biochem Biophys Res Commun       Date:  1999-10-22       Impact factor: 3.575

9.  Tobacco smoke is a source of toxic reactive glycation products.

Authors:  C Cerami; H Founds; I Nicholl; T Mitsuhashi; D Giordano; S Vanpatten; A Lee; Y Al-Abed; H Vlassara; R Bucala; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

10.  Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression.

Authors:  P Fioretto; M W Steffes; D E Sutherland; M Mauer
Journal:  Kidney Int       Date:  1995-12       Impact factor: 10.612

View more
  75 in total

Review 1.  S100 proteins in cartilage: role in arthritis.

Authors:  Raghunatha R Yammani
Journal:  Biochim Biophys Acta       Date:  2012-01-12

Review 2.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

Review 3.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

4.  Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression.

Authors:  Weijing Cai; John Cijiang He; Li Zhu; Xue Chen; Sylvan Wallenstein; Gary E Striker; Helen Vlassara
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

Review 5.  Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

Authors:  Aowen Zhuang; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-06-06       Impact factor: 2.916

6.  Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons.

Authors:  Helen Vlassara; Jaime Uribarri; Luigi Ferrucci; Weijing Cai; Massimo Torreggiani; James B Post; Feng Zheng; Gary E Striker
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

7.  Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia.

Authors:  Massimo Torreggiani; Huixian Liu; Jin Wu; Feng Zheng; Weijing Cai; Gary Striker; Helen Vlassara
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

8.  AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease.

Authors:  Weijing Cai; Massimo Torreggiani; Li Zhu; Xue Chen; John Cijiang He; Gary E Striker; Helen Vlassara
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-02       Impact factor: 4.249

Review 9.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

10.  Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1.

Authors:  Weijing Cai; Maya Ramdas; Li Zhu; Xue Chen; Gary E Striker; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.